BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27652012)

  • 1. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions.
    Zhao J; He Q; Gong Z; Chen S; Cui L
    Springerplus; 2016; 5(1):1436. PubMed ID: 27652012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1α-Dependent Inhibition of Wnt/β-Catenin.
    Cui L; Zhao J; Liu J
    Am J Med Sci; 2018 Mar; 355(3):274-280. PubMed ID: 29549930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.
    Li Z; Li Q; Wang G; Huang Y; Mao X; Zhang Y; Wang X
    Am J Transl Res; 2017; 9(8):3776-3786. PubMed ID: 28861168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
    Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
    Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
    Wei W; Liu H; Yuan J; Yao Y
    Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
    Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
    Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
    Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
    Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
    Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
    Zhou J; Jin B; Jin Y; Liu Y; Pan J
    Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
    Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
    Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.
    Chen L; Wang L; Shen H; Lin H; Li D
    Biochem Biophys Res Commun; 2017 Mar; 484(2):416-421. PubMed ID: 28137584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling.
    Li H; Jiao S; Li X; Banu H; Hamal S; Wang X
    Biochem Biophys Res Commun; 2015 Nov; 467(1):14-20. PubMed ID: 26427870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma.
    Xiong L; Tang Y; Liu Z; Dai J; Wang X
    Springerplus; 2016; 5(1):1626. PubMed ID: 27722045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niclosamide, a Drug with Many (Re)purposes.
    Kadri H; Lambourne OA; Mehellou Y
    ChemMedChem; 2018 Jun; 13(11):1088-1091. PubMed ID: 29603892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
    Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
    Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity.
    Li J; Jiang Y; Wang P; Ke S; Yang L; Shen Y
    Anticancer Drugs; 2019 Aug; 30(7):e0747. PubMed ID: 31305293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.